Previous 10 | Next 10 |
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™ PR Newswire Commercial launch expected in 2Q 2022 SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Shares of Lipocine Inc. (NASDAQ:LPCN) traded today at $1.75, eclipsing its 52-week high. This new high was reached on approximately average trading volume as 767,000 shares traded hands, while the average 30-day volume is approximately 722,000 shares. Lipocine Inc. (NASDAQ:LPCN) defies a...
Lipocine press release (NASDAQ:LPCN): FY GAAP EPS of -$0.01. Revenue of $16.1M. As of December 31, 2021, the company had $44.6 million of unrestricted cash, cash equivalents, and marketable investments, compared to $19.7 million of unrestricted cash, cash equivalents ...
Lipocine Announces Financial Results for the Year Ended December 31, 2021 PR Newswire SALT LAKE CITY , March 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today ...
Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH PR Newswire SALT LAKE CITY , March 1, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today ...
Lipocine (LPCN) shares are trading higher after announcing that the FDA accepted the New Drug Application ("NDA") resubmission for Tlando (testosterone undecanoate), a potential rival for Jatenzo from Clarus Therapeutics (NASDAQ:CRXT). The federal agency has designated the marketing applicati...
LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO® PDUFA target action date set for March 28, 2022 PR Newswire SALT LAKE CITY , Feb. 3, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceuti...
Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® PR Newswire SALT LAKE CITY , Jan. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine d...
Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference PR Newswire SALT LAKE CITY , Jan. 5, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announ...
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 PR Newswire SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 r...